Self-Assembled Nanoparticles with Kynureninase-Fc Fusion Protein and Pheophorbide A for Photodynamic Immunometabolic Cancer Therapy.

ABSTRACT:

Background/objectives

Aberrant metabolism in tumors exacerbates the immunosuppressive tumor microenvironment. The immunosuppressive metabolite kynurenine inhibits the activation of effector T cells. Current antitumor drugs targeting kynurenine focus on small molecule inhibitors, which exhibit suboptimal efficacy in suppressing kynurenine generation owing to the diversity of kynurenine synthesis pathways. In contrast, kynureninase (KYNase) can directly metabolize kynurenine regardless of the production source. However, its delivery is hindered by short blood-circulation half-life and poor tumor accumulation. Additionally, photodynamic therapy (PDT) has been reported to synergize with immunotherapy, suggesting a potential combinatorial photodynamic immunometabolic cancer therapy with

SUBMITTER: Zhang C 

PROVIDER: S-EPMC12942165 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature